Author

S. S. Good

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Pharmacology & Toxicology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Research Focus:host-pathogen & immune response· 2 Organism:human· 1 Organism:mouse· 1

Frequent Co-Authors

A. Moussa· 2 shared A. Weight· 1 shared B. Canard· 1 shared G. Collu· 1 shared J. G. Julander· 1 shared J. Westover· 1 shared J.-P. Sommadossi· 1 shared K. H. Jung· 1 shared

Activity by Year

2020-2021 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 27 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersPharmacology & Toxicology

A. Moussa

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

AT-752, a double prodrug of a guanosine nucleotide analog, inhibits yellow fever virus in a hamster model

K. Lin, S. S. Good, J. G. Julander, A. Weight, A. Moussa

This paper demonstrates that AT-752, a prodrug of a guanosine nucleotide analog, reduces YFV viremia and liver damage in hamsters and improves survival rates.

bioRxiv · Oct 25, 2021Pharmacology & Toxicology

AT-527 is a potent in vitro replication inhibitor of SARS-CoV-2, the virus responsible for the COVID-19 pandemic

S. S. Good, J. Westover, K. H. Jung, P. La Colla, G. Collu, A. Moussa, B. Canard, J.-P. Sommadossi

The paper reports that AT-511, a form of AT-527, is a potent in vitro inhibitor of SARS-CoV-2 replication with low cytotoxicity.

bioRxiv · Aug 11, 2020 · PreprintPharmacology & Toxicology